China included SSY's (HKG:2005) stiripentol dry suspension and its etomidate medium/long chain fat emulsion injection in its insurance reimbursement drug catalog, according to a Monday filing with the Hong Kong Exchange.
Stiripentol is indicated for the treatment of myoclonic epilepsy in children, while etomidate is for general anesthesia induction, the filing said.
Shares jumped 1% during Monday's afternoon trading.